Sequent Scientific Limited announced the successful completion of its composite scheme of amalgamation with Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited. The National Company Law Tribunal's order sanctioning the scheme was filed with the Registrar of Companies on December 16, 2025, making this the Effective Date 2. As part of the scheme's effectiveness, the Board of Directors approved the allotment of 18,19,21,827 equity shares of Sequent to the shareholders of Viyash Life Sciences, based on a share exchange ratio of 56 Sequent shares for every 100 Viyash shares. This allotment will increase Sequent's issued and paid-up equity share capital. The company also approved the allotment of 2,03,41,257 share warrants to Viyash's warrant holders at an issue price of ₹181.94 per warrant, with 25% of the issue price received as upfront payment. Furthermore, significant changes in management were approved. Dr. Haribabu Bodepudi has been appointed as the Managing Director and Group Chief Executive Officer for a period of two years, effective December 16, 2025. Mr. Rajaram Narayanan's designation has been changed to Wholetime Director, designated as Chief Executive Officer – Animal Health, effective the same date. Mr. Srinivas Vasireddy has been appointed as an Additional Director (Wholetime and Non-Independent) for two years from December 16, 2025. The company also announced the appointment of Mr. Ramakant Singani as Chief Financial Officer and Key Managerial Personnel, effective January 1, 2026, and noted the resignation of Mr. Saurav Bhala from the same position, also effective January 1, 2026. Other key outcomes include CA Hull Investments becoming a promoter of Sequent and the alteration of Sequent's Memorandum and Articles of Association to reflect an increased authorized share capital of ₹8,861.47 crore. Sequent Research Limited ceased to be a wholly-owned subsidiary, while Appco Pharma LLC became a material subsidiary.